Zai Lab (NASDAQ:ZLAB) CFO Sells $50,933.96 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 1,438 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $35.42, for a total value of $50,933.96. Following the sale, the chief financial officer owned 16,720 shares of the company’s stock, valued at approximately $592,222.40. This trade represents a 7.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Yajing Chen also recently made the following trade(s):

• On Friday, August 8th, Yajing Chen sold 4,096 shares of Zai Lab stock. The stock was sold at an average price of $34.01, for a total value of $139,304.96.
• On Thursday, June 26th, Yajing Chen sold 2,675 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total value of $96,647.75.
• On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The shares were sold at an average price of $30.00, for a total value of $288,540.00.

Zai Lab Stock Down 5.5%

Shares of NASDAQ:ZLAB opened at $33.50 on Thursday. The business has a 50 day moving average price of $36.38 and a 200 day moving average price of $33.66. Zai Lab Limited Unsponsored ADR has a twelve month low of $16.93 and a twelve month high of $44.34. The company has a market cap of $3.72 billion, a price-to-earnings ratio of -16.42 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%.The firm had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. Analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds have recently modified their holdings of ZLAB. GF Fund Management CO. LTD. acquired a new position in shares of Zai Lab in the 4th quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Zai Lab in the 1st quarter worth approximately $75,000. Barclays PLC raised its holdings in shares of Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares in the last quarter. Advisors Preferred LLC acquired a new position in shares of Zai Lab in the 1st quarter worth approximately $110,000. Finally, Palumbo Wealth Management LLC acquired a new position in shares of Zai Lab in the 1st quarter worth approximately $203,000. 41.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ZLAB shares. Wall Street Zen downgraded Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Citigroup restated a “buy” rating and set a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Leerink Partners set a $75.00 target price on Zai Lab and gave the company an “outperform” rating in a research note on Monday, June 30th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.22.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.